The St.Joseph’s liver program was created to maintain a balance between prevention, early diagnosis, treatment, liver transplant evaluation and clinical trials. We take nothing for granted and go the extra distance to make sure our patients receive the absolute best care possible. Although we are a major teaching institution, we drill into our resident physicians, the concept that we treat our patients as if they were our own family, i.e. “if that were your mom, what would you do for her?”

Services we provide Include:
1) Treatment of liver disease:
Cirrhosis
Liver cancer screening
Hepatitis C
Hepatitis B
Fatty liver disease
Non-Alcoholic-Steato-Hepatitis (NASH)
Alcoholic liver damage
Autoimmune hepatitis
Primary Biliary Cholangitis/Cirrhosis
Primary Sclerosing Cholangitis
Hemochromatosis
Wilson’s Disease
alpha-one-anti-trypsin disease

2) Portal Hypertension: TIPS procedure, Surgical shunt, BRTO

3) Liver cancer and Bile duct cancer care:

a. Surgical: open and laparoscopic liver resection, bile duct resection and reconstruction
b. Non-surgical: hepatic artery chemo-embolization, Yttrium 90 hepatic artery infusion, Radiofrequency ablation


4) Liver Transplant Evaluation in collaboration with several major transplant centers

5) Clinical Trials

The Center for Liver Disease and Cancer Care at St. Joseph's Medical Center: Multidisciplinary Treatment and Surgical Care

1135 Broad St, 3rd flr
Clifton, NJ 07013
158 14th St, 1st floor
Hoboken, NJ 07030
224 Hamburg Turnpike
Wayne, NJ 07470
Phone: 973-754-2315
Fax: 973-754-3528
Stacks Image 399
Stacks Image 468

Hepatic Elastography is a special type of ultrasound that can identify patients with advanced liver damage (cirrhosis) who need routine liver cancer testing.

Hepatic elastography is available at St Joseph's Outpatient Radiology located at
1135 Broad St, Clifton New Jersey

Call 973-569-6300 for more information and an appointment




Support Senate bill No. 1279 requiring hospitals and health care professionals to offer hepatitis C testing to patients born between 1945 and 1965

American Association for the Study of Liver Disease HCV Guidelines



Clinical Trials:


Liver Disease:
A Phase 3b, Double‑Blind, Randomized, Placebo‑Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis’
Sponsor: Intercept, NCT02308111

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis
Sponsor: Intercept, NCT02548351

Liver Cancer
A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Advanced Hepatocellular Carcinoma Subjects with or without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects who are Naive to Systemic Therapy
Sponsor: BMS, NCT016588782016

A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
Sponsor: Sillajen, NCT02562755